Rachel Miller, lead nurse and head of patient services at Anthony Nolan, said:
“We’re delighted NICE has recommended ruxolitinib as a treatment for patients with acute graft versus host disease (aGvHD).
“GvHD can be debilitating for patients and has a significant impact on recovery following stem cell transplant. The approval of this effective drug that can be taken as a tablet at home marks a significant step forward and will be a huge relief to patients who struggle to travel for treatment.
“Clinical trial evidence shows that ruxolitinib can reduce the need for further treatment and improves quality of life overall for patients with aGvHD.
“We extend our heartfelt thanks to the patients and families who shared their stories to help make this outcome possible. Their voices have been instrumental in ensuring more people have access to this life-changing treatment.”
You can read NICE's final draft guidance here.